BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

...with €2.5 million ($3.3 million) in seed funding from M Ventures, first aimed to develop CALY-001...
...in parallel on IL-15 antagonist CALY-002 began to capture investors’ attention, and the company out-licensed CALY-001’s...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...and Phase I testing to treat solid tumors. Calypso Biotech S.A. has the anti-MMP9 mAb CALY-001...
BioCentury | Apr 7, 2017
Company News

Calypso, EA Pharma deal

...Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001 . The...
...Calypso Biotech S.A. , Geneva, Switzerland EA Pharma Co. Ltd. , Tokyo, Japan Business: Gastrointestinal Julian Zhu CALY-001 Calypso...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 9 (MMP9); netrin 1 (NTN1)

...treat chronic obstructive pulmonary disease (COPD), rheumatoid arthritis and solid tumors. Calypso Biotech S.A. has CALY-001...
BioCentury | May 27, 2013
Emerging Company Profile

Calypso: Fistula fix

...co-VPs of R&D Alain Vicari and Yolande Chvatchko worked on the human mAbs, dubbed the CALY-001...
...senior director at the Merck Serono Geneva Research Centre. Vicari said the target of the CALY-001...
...aiming for is associated with fistulae in human disease," he said. Vicari did confirm that CALY-001...
BioCentury | May 20, 2013
Company News

Calypso Biotech, iDD Biotech deal

...to develop Merck Serono's preclinical R&D portfolio for gastrointestinal immunological disorders. Calypso's pipeline also includes CALY-001...
Items per page:
1 - 6 of 6